Chemokeyp: A Feasibility Study to Evaluate and Further Develop Patient Safety Software Enabling Efficient and Effective Information Exchange for Patients Undergoing Systemic Cancer Treatment Who Access Emergency or Unscheduled Care

What this Trial Is About

Researchers are evaluating the Chemokeyp system, a secure digital platform designed to improve communication between Oncology and Emergency Department (ED) teams for patients receiving chemotherapy who may have treatment-related complications. This observational feasibility study aims to test whether ED clinicians can efficiently use a checklist to capture data on serious adverse events in real time, supporting earlier notification to research teams and informing future safety tools for patients undergoing systemic cancer treatment. Participants enrolled in this study receive a medical-alert wristband with a QR code that ED staff can scan upon the patient's unscheduled care visit. After authentication, clinicians complete a structured checklist covering possible serious symptoms such as infection, chest pain, vomiting, or syncope. The platform serves solely as a research data-capture tool and does not interact with hospital electronic health records or clinical decision systems, nor does it alter usual clinical care. During the study, researchers will assess the time it takes to become aware of a chemotherapy patient attending the ED, aiming to reduce this to within 48 hours. Data accuracy will be checked against verified serious adverse events. The study involves monitoring checklist completion, studying communication effectiveness, and supporting patient safety. The research is sponsored by St Vincent's University Hospital, Ireland, and is expected to continue until January 2027.

Chemokeyp: A Feasibility Study for Realtime Safety Data-Capture for Potential Serious Adverse Drug Events